Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients

Abstract

There are limited data regarding the feasibility of transitioning from intravenous prostacyclins to selexipag in pulmonary arterial hypertension patients. We present a case series of successful transitions from intravenous prostacyclins to selexipag in the majority of carefully selected five stable pulmonary arterial hypertension patients using a standardized protocol in the outpatient setting.

Keywords

• pulmonary arterial hypertension
• pulmonary vasodilators
• the United States Registry to Evaluate Early and Long‐term PAH disease management (REVEAL)